This journal is a member of the Committee on Publication Ethics (COPE).
As of 1st January 2018 the article processing charge (APC)* will increase to $895 USD. The APC is based on the date of original submission so all articles submitted before 1st January 2018 will remain eligible for the lower price regardless of the article's date of acceptance. The journal’s current APC is $715 USD.
If you have any questions, please contact the Editorial Office at email@example.com.
Rare Tumors is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/raretumors to login and submit your article online.
*The article processing charge (APC) is payable when the manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.
Rare Tumors is an open access, peer-reviewed international medical journal devoted entirely to the study, diagnosis, and treatment of rare cancers. The journal covers the diagnosis, classification, and treatment of rare tumors and hematological malignancies for physicians and medical scientists interested in uncommon neoplasms. The primary intent of the journal will be to publish clinically relevant information that will directly improve the care of patients with rare cancers. Basic science studies of interest to those treating rare malignancies will also be considered for publication when relevant. A special section of the journal is dedicated to Case Reports: we would like to invite clinicians and researchers to send us their reports.
|Prakash Adhikari||Department of ENT and Head and Neck Surgery, GMS, Memorial Academy of ENT and Head and Neck Studies, TU Teaching Hospital, Kathmandu, Nepal|
|Abbas Agaimy||Department of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany|
|Khan Shah Alam||Department of Orthopaedics, All India Institute of Medical Sciences Ansari Nagar, New Delhi, India|
|Rafael Álvarez-González||Graduate School of Biomedical Sciences, University of North Texas, Health Science Center at Forth Worth, Texas, USA|
|Ramon Andrade de Mello||Department of Medical Oncology, Oncology Portuguese Institute of Porto Francisco Gentil, Porto, Portugal|
|Armando Bartolazzi||Department of Pathology, St. Andrea University Hospital, Rome, Italy|
|Sumita Bhatia||Medical Center Drive, West Hills, CA, USA|
|Archit Bhatt||Department of Neurology and Ophtalmology, Clinical Center East Lansing, East Lansing, Michigan, USA|
|Maikel Elia Botros||Quillen College of Medicine, Johnson City, TN, USA|
|Kevin Camphausen||Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA|
|Joseph R. Carver||Abramson Cancer Center, University of Pennsylvania, Pennsylvania, USA|
|Ashish V. Chintakuntlawar||Department of Hematology and Oncology, Mayo Clinic, Rochester, MN, USA|
|William Cho||Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong|
|Domenico Coppola||Anatomic Pathology and Neuroendocrine Cancer Research Divisions, Moffit Cancer Center and Research Institute, Tampa, Florida, USA|
|Patricia Devilliers||Department of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, USA|
|Ozsahin E. Mahmut||Department of Radiooncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|
|Jimmy Thomas Efird||Centre of Health Vulnerable Populations, University of Carolina, Greensboro, Carolina, USA|
|Amany Elwakkad||National Research Center, Cairo, Egypt|
|Gulgun Engin||Department of Radiology, Faculty of Medicine, Istanbul University, Istanbul, Turkey|
|Guy Eslick||Harvard School of Public Health, MA, USA|
|Undurti N. Fams Das||UND Life Sciences, Shaker Heights, Ohio, USA|
|Faris Farassati||Department of Medicine, University of Kansas School of Medicine, Kansas City, Kansas, USA|
|Paulette M. Fauceglia||Roswell Park Cancer Institute, Buffalo, New York, USA|
|Luis E. Fayad||Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA|
|Ali Gholamrezanezhad||Research Institute for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran|
|Thorvardur Halfdanarson||University of Iowa Hospitals and Clinics and Iowa City VA Medical Center,Iowa City, Iowa, USA|
|Paul H. Hartel||Broaddus Hospital of Davis Health System, Elkins, West Virginia, USA|
|Joseph Herman||Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore Maryland USA|
|Kanya Honoki||Department of Orthopedic Surgery, Nara Medical University, Nara, Japan|
|Charles Hsu||Department of Radiation Oncology, University of California - San Francisco, San Francisco, California, USA|
|Sergio Huerta||Dallas VA Medical Center Surgical Services, Dallas, Texas, USA|
|Abdul Hussain||Minimal Access Unit, General Surgery Department, Princess Royal University Hospital, London, UK|
|Sachin B. Ingle||Department of Pathology, MIMSR Medical College, Latur, Maharashtra, India|
|Rafael Jimenez||Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA|
|Bleddyn Jones||Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK|
|Babak Kateb||Intraoperative Surgical Planning Society, Los Angeles, CA, USA|
|Sunali Khanna||Department of Oral Medicine & Radiology, Nair Hospital Dental College, Mumbai, India|
|Boris Kirshtein||Department of Surgery, Soroka University Medical Center, Beer Sheva, Israel|
|Antoniades Konstantinos||School of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece|
|Masafumi Koshiyama||Department of Ob/Gy at Otsu Red Cross Hospital, Otsu, Japan|
|Sunil Krishnan||Radiation Oncology, Gastrointestinal Translational Research, M.D. Anderson Cancer Center, Houston, TX, USA|
|Calin Lazar||Department of Plastic and Reconstructive Surgery, Rouen University Hospital, Rouen, France|
|Samy Lewiz Habib||Department of Medicine, Division of Nephrology, University of Texas Health Science Center, San Antonio, Texas, USA|
|Wei Li||Institute of Biomedical Engineering, School of Control Science and Engineering, Shandong University, Shandong, China|
|Simon Lo||Department of Radiation Oncology, Case Western Reserve University, UH Seidman Cancer Center, Cleveland, OH, USA|
|Lorenzo Lo Muzio||Surgical Sciences Department, Faculty of Medicine, University of Foggia, Foggia, Italy|
|Sridhar Mani||Departments of Medicine and Molecular Genetics, Division of Oncology, Albert Einstein School of Medicine, New York, USA|
|Hiroyuki Matsubayashi||Shizuoka Cancer Center, Shizuoka-ken, Japan|
|Toshihiro Matsuo||National Hospital Organization Kure Medical Center, Chugoku Cancer Center, Kure City, Hiroshima, Japan|
|Axel Merseburger||Klinik und Poliklinik für Urologie, Universitätsklinikum Schleswig-Holstein, Campus Luebeck, Germany|
|Oliver Micke||Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Bielefeld, Germany|
|Rene Mirimanoff||Service de Radio-Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|
|Luca Morelli||Operative Unit of Patological Anatomy and Cytological Diagnostics, P.O. S. Chiara, Hospital of Trento, Trento, Italy|
|Charbel D. Moussallem||Orthopedic Surgery, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon|
|Hidenari Nagai||Division of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, Tokyo, Japan|
|Tan Dat Ngyuen||Department of Radiation Oncology, Institut Jean-Godinot, Reims, France|
|Athanasios Papatsoris||University of Athens, Athens, Greece|
|Nicholas A. Pavlidis||Department of Medical Oncology, School of Medicine, University of Ioannina, Ioannina, Greece|
|Yi Chu Pei||Department of Surgical Pathology, Changhua Christian Hospital, Changhua, Taiwan|
|Shahid Pervez||Department of Pathology and Microbiology, Agakhan University Hospital, Karachi, Pakistan|
|Fernando Quevedo||Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA|
|Ghulam Sarwar Hashmi||Department of Oral and Maxillofacial Surgery, Z.A. Dental College, Medical Colony, A.M.U. Aligarh, India|
|Malcolm Schinstine||Division of Pathology, Hilo Medical Center Laboratories, Hilo, Hawaii, USA|
|Andrzej Semczuk||Lublin Medical University, Lublin, Poland|
|Mari Shimura||Dept. of Intractable Diseases, Research Institute, International Medical Center of Japan, Tokyo, Japan|
|Vernon Keith Sondak||Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA|
|Giuseppe Spriano||Department of Otolaryngology/Head and Neck Surgery, National Cancer Institute Regina Elena, Rome, Italy|
|Keith Stubbs||University of Western Australia, Perth, Australia|
|Fabio Tavora||Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, DC, USA|
|Juliette Thariat||Department of Radiation Oncology, Anti Cancer Center Antoine-Lacassagne, University Nice Sophia-Antipolis, Nice, France|
|Takeshi Tomonaga||Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba Japan|
|Jonathan C. Trent||The University of Texas MD Anderson Cancer Center, TX, USA|
|Mark Gerard Trombetta||Department of Radiation Oncology, West Penn Allegheny Health System Allegheny General Hospital, PA, USA|
|Gamze Ugurluer||Department of Radiation Oncology, Acibadem Adana Hospital, Acibadem University, Adana, Turkey|
|Lyuba Varticovski||Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA|
|Salvador Villa I Freixa||Department of Radiation Oncology, Hospital Universitari Germans Trías, Badalona, Catalunya, Spain|
|Takuya Watanabe||Watanabe Internal Medicine Aoyama Clinic, Aoyama, Nishiku, Niigata, Japan|
|Shigeru Yamada||Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan|
|Leandra Náira Zambelli Ramalho||Department of Pathology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirdo Preto, SP, Brazil|
- Open Access
- Article processing charge (APC)
- What do we publish?
3.1 Aims & scope
3.2 Article types
3.3 Writing your paper
- Editorial policies
4.1 Peer review policy
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical trials
4.8 Reporting guidelines
- Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement
- Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplementary material
6.4 Reference style
6.5 English language editing services
- Submitting your manuscript
7.1 How to submit your manuscript
7.2 Title, keywords and abstracts
7.3 Information required for completing your submission
- On acceptance and publication
8.1 SAGE Production
8.2 Online publication
8.3 Promoting your article
- Further information
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/raretumors to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Rare Tumors will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Rare Tumors is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license.
As of 1st January 2018, the article processing charge (APC) will increase to $895 USD*. The APC is based on the date of original submission so all articles submitted before 1st January 2018 will remain eligible for the lower price regardless of the article's date of acceptance. The journal’s current APC is $715 USD*.
*If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.
Before submitting your manuscript to Rare Tumors, please ensure you have read the Aims & Scope.
Original Articles have a word limit of 3,500 words, require a structured abstract (see below for more details on this) and no more than 5 tables and/or figures
The structured abstract should have the following sub headings: Background, Objective, Methods, Result and Conclusion.
The structure of the manuscript should be Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusions and
Reviews have a word limit of 4,000 words, require an abstract with a word limit of 250 words, a short introduction (see below for more details), a minimum of 40 references and no more than 5 tables and/or figures.
The Abstract should be a general summary of content, to be followed by an Introduction, putting the study into context and defining the aim. Reviews should concentrate on the most recent developments in the field and should clearly describe the search strategy, including keywords, inclusion and exclusion criteria, search engines, etc.
This article type does not have a standard format but all sections should be designated with headings.
Brief Reports have a word limit of 2,000 words, require an unstructured abstract with a limit of 150 words, a reference limit of 20 and no more than 3 tables and/or figures.
This article type is for short reports of results from original research and must provide conclusive findings. Preliminary observations or incomplete findings will not be considered for publication.
Case Reports have a word limit of 2,000 words, require unstructured abstracts with a word count of 150 words, have a reference limit of 20 and no more than 3 tables and/or figures.
Case Reports should describe observations on clinical cases that can be educational, including adverse effects of drugs or outcomes of a specific treatment.
The manuscript should be structured as follows: Abstract, Introduction (optional), Case Report(s), Discussion, Conclusion and References.
Letters to the Editor have a word limit of 800 words and are written on the invitation of the Editor.
This article type is short essays that express the authors’ viewpoint, may respond to published manuscripts in our journals, or deliver information or news regarding an issue related to the Journal scope. If the letter relates to a published manuscript, the authors of the original manuscript will be given the opportunity to provide a respond. Authors of Letters to the Editor should provide a short title.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
3.3.1 Making your article discoverable
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online
Following a preliminary triage to eliminate submissions unsuitable for Rare Tumors all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication. If your paper should be considered for fast-track publication, please explain why.
The journal’s policy is to have manuscripts reviewed by two expert reviewers. Rare Tumors utilizes a single-blind peer review process in which the reviewer’s name and information is withheld from the author. Reviewers may at their own discretion opt to reveal their names to the author in their review but our standard policy practice is for their identities to remain concealed. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor-in-Chief who then makes the final decision.
Rare Tumors is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for Rare Tumors can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.
Please note that all manuscripts should be accompanied by a separate document entitled ‘Declarations’.
Please read the Declarations guidelines for authors, available here, carefully before submitting your Declarations document.
This should be submitted under the file designation ‘Declarations’. This must include each of the below headings with the corresponding information. Please note that manuscripts which do not include these Declarations will be returned. These declarations may be published at the end of accepted manuscripts. Where one of these headings is not applicable please indicate as such under the heading.
1. Conflicting interests
3. Informed consent
4. Ethical approval
Example of a completed Declarations document:
Conflicting interests: MS is an employee of XXX. BF has received grants from XXX.
Funding: This work was supported by the Medical Research Council [grant number XXX]
Informed consent: Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.
Ethical approval: Ethical approval for this study was obtained from *NAME OF ETHICS COMMITTEE OR INSTITUTIONAL REVIEW BOARD (APPROVAL NUMBER/ID)*.
Contributorship: BF and NP researched literature and conceived the study. MS was involved in protocol development, gaining ethical approval, patient recruitment and data analysis. BF wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript
Acknowledgements: We would like to thank XXX XXXX for his assistance and guidance in this research.
Please read the following information carefully for additional information regarding these declarations.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.
It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Rare Tumors requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Rare Tumors to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.
Rare Tumors conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
Rare Tumors requests all authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at Neisha.Jobanputra@sagepub.co.uk.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
Rare Tumors and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Rare Tumors publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines
Figures supplied in color will appear in color online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.
Rare Tumors adheres to the SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Rare Tumors is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/raretumors to login and submit your article online.
For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognized.
We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximize your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Rare Tumors editorial office as follows: